Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000628697 | SCV000749603 | likely benign | Bloom syndrome | 2024-09-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001019548 | SCV001180920 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003420088 | SCV004117441 | uncertain significance | BLM-related disorder | 2023-05-11 | criteria provided, single submitter | clinical testing | The BLM c.960-4G>A variant is predicted to interfere with splicing. This variant is predicted to alter splicing based on available splicing prediction programs (Alamut Visual Plus v1.6.). However, such computer prediction programs are imperfect. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant has conflicting interpretations in Clinvar ranging from likely benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/524826/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |